http://orcid.org/0000-0001-6124-6897
Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ahmad Shamabadi, Ali Ahmadzade, Kasra Pirahesh, Alireza Hasanzadeh & Hassan Asadigandomani. (2023) Suicidality risk after using cannabis and cannabinoids: An umbrella review. Dialogues in Clinical Neuroscience 25:1, pages 50-63.
Read now
Read now
Benedikt Fischer, Wayne Hall, Thiago M. Fidalgo, Eva Hoch, Bernard Le Foll, Maria-Elena Medina-Mora, Jens Reimer, Philip G. Tibbo & Didier Jutras-Aswad. (2023) Recommendations for Reducing the Risk of Cannabis Use-Related Adverse Psychosis Outcomes: A Public Mental Health-Oriented Evidence Review. Journal of Dual Diagnosis 19:2-3, pages 71-96.
Read now
Read now
Boris Karpov, Maija Lindgren, Tuula Kieseppä, Asko Wegelius & Jaana Suvisaari. (2022) Cognitive functioning and cannabis use in first-episode psychosis. Nordic Journal of Psychiatry 76:7, pages 551-558.
Read now
Read now
Mark Mohan Kaggwa, Felix Bongomin, Sarah Maria Najjuka, Godfrey Zari Rukundo & Scholastic Ashaba. (2021) Cannabis-Induced Mania Following COVID-19 Self-Medication: A Wake-Up Call to Improve Community Awareness. International Medical Case Reports Journal 14, pages 121-125.
Read now
Read now
Raul Felipe Palma-Álvarez, Albert Soriano-Dia, Elena Ros-Cucurull, Constanza Daigre, Pedro Serrano-Pérez, Germán Ortega-Hernández, Marta Perea-Ortueta, David Gurrea Salas, Josep-Antoni Ramos-Quiroga & Lara Grau-López. (2021) Catatonia Related to Cannabis and Synthetic Cannabinoids: A Review. Journal of Dual Diagnosis 17:2, pages 159-171.
Read now
Read now
Wayne Hall. (2020) The costs and benefits of cannabis control policies
. Dialogues in Clinical Neuroscience 22:3, pages 281-287.
Read now
Read now
Articles from other publishers (60)
Kelly K. Anderson, Rebecca Rodrigues, Britney Le, Maliha Mamun, Suzanne Archie, Jordan Edwards, Tara Elton-Marshall, Jason Gilliland, Daniel Thomas Myran, Lena Palaniyappan, Christopher M. Perlman, Jamie A. Seabrook, Robin M. Murray & Salimah Z. Shariff. (2024) Impact of non-medical cannabis legalization with market restrictions on health service use and incident cases of psychotic disorder in Ontario, Canada. International Journal of Drug Policy 123, pages 104285.
Crossref
Crossref
Jared C Wootten, Rebecca Rodrigues, Jason Gilliland, Brooke Carter, Salimah Z Shariff, Shiran Zhong, Suzanne Archie, Jordan Edwards, Tara Elton-Marshall, Daniel Thomas Myran, Lena Palaniyappan, Christopher M Perlman, Jamie A Seabrook, Robin M Murray & Kelly K Anderson. (2023) The effect of non-medical cannabis retailer proximity on use of mental health services for psychotic disorders in Ontario, Canada. International Journal of Social Psychiatry.
Crossref
Crossref
Liza Hopkins, Richard Whitehead & Glenda Pedwell. (2023) Integrating Substance Misuse Specialists in a Youth Early Psychosis Service: Increasing Mental Health Clinicians’ Knowledge and Confidence. Community Mental Health Journal 59:7, pages 1321-1329.
Crossref
Crossref
Isobel McMahon, Laura M. Harris-Lane, Jennifer Donnan, Lisa Bishop & Nick Harris. (2023) Emerging adult perceptions of higher-risk cannabis consumption behaviours. Harm Reduction Journal 20:1.
Crossref
Crossref
Matthew N. Hill, Margaret Haney, Cecilia J. Hillard, Debra S. Karhson & Haley A. Vecchiarelli. (2023) The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses. Psychological Medicine, pages 1-19.
Crossref
Crossref
James Hotham, Rebecca Cannings-John, Laurence Moore, Jemma Hawkins, Chris Bonell, Matthew Hickman, Stanley Zammit, Lindsey A. Hines, Linda Adara, Julia Townson & James White. (2023) Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents. The British Journal of Psychiatry, pages 1-7.
Crossref
Crossref
Jonathan Fridman, Esther Bloemhof-Bris, Shira Weizman, Tal Kessler, Dorit Porat, Amos Ivry, Aviva Wolf, Rafael Stryjer & Assaf Shelef. (2023) Inflammation Markers Among Schizophrenia Patients Who Use Cannabis. Clinical Neuropharmacology 46:4, pages 145-148.
Crossref
Crossref
Matthew D. Albaugh, Max M. Owens, Anthony Juliano, Jonatan Ottino-Gonzalez, Renata Cupertino, Zhipeng Cao, Scott Mackey, Claude Lepage, Pierre Rioux, Alan Evans, Tobias Banaschewski, Arun L. W. Bokde, Patricia Conrod, Sylvane Desrivières, Herta Flor, Antoine Grigis, Penny Gowland, Andreas Heinz, Bernd Ittermann, Jean-Luc Martinot, Marie-Laure Paillère Martinot, Eric Artiges, Frauke Nees, Dimitri Papadopoulos Orfanos, Tomáš Paus, Luise Poustka, Sabina Millenet, Juliane H. Fröhner, Michael N. Smolka, Henrik Walter, Robert Whelan, Gunter Schumann, Alexandra Potter & Hugh Garavan. (2023) Differential associations of adolescent versus young adult cannabis initiation with longitudinal brain change and behavior. Molecular Psychiatry.
Crossref
Crossref
Feten Fekih-Romdhane, Abir Hakiri, Manel Stambouli, Wissal Cherif, Rami Away, Amani Amri, Majda Cheour & Souheil Hallit. (2023) Schizotypal traits in a large sample of high-school and university students from Tunisia: correlates and measurement invariance of the arabic schizotypal personality questionnaire across age and sex. BMC Psychiatry 23:1.
Crossref
Crossref
Haley C. R. Bernusky, Philip G. Tibbo, Patricia J. Conrod, Fakir Md. Yunus, Matthew T. Keough, Kara D. Thompson, Marvin D. Krank, Allyson F. Hadwin & Sherry H. Stewart. (2023) Do Anxiety Symptoms Mediate the Association Between Cannabis Use Frequency and Psychotic-Like Experiences in Emerging Adult Undergraduates?. The Canadian Journal of Psychiatry, pages 070674372311769.
Crossref
Crossref
Matteo Scopetti, Donato Morena, Federico Manetti, Alessandro Santurro, Nicola Di Fazio, Stefano D’Errico, Martina Padovano, Paola Frati & Vittorio Fineschi. (2023) Cannabinoids and Brain Damage: A Systematic Review on a Frequently
Overlooked Issue. Current Pharmaceutical Biotechnology 24:6, pages 741-757.
Crossref
Crossref
Raul Felipe Palma-Álvarez, Constanza Daigre, Elena Ros-Cucurull, Marta Perea-Ortueta, Germán Ortega-Hernández, Ana Ríos-Landeo, Carlos Roncero, Josep Antoni Ramos-Quiroga & Lara Grau-López. (2023) Clinical features and factors related to lifetime suicidal ideation and suicide attempts in patients who have had substance-induced psychosis across their lifetime. Psychiatry Research 323, pages 115147.
Crossref
Crossref
N. Lamanna-Rama, K.S. MacDowell, G. López, J.C. Leza, M. Desco, E. Ambrosio & M.L. Soto-Montenegro. (2023) Neuroimaging revealed long-lasting glucose metabolism changes to morphine withdrawal in rats pretreated with the cannabinoid agonist CP-55,940 during periadolescence. European Neuropsychopharmacology 69, pages 60-76.
Crossref
Crossref
Lavinia Baltes-Flueckiger, Regine Steinauer, Maximilian Meyer, Marc Vogel & Marc Walter. (2023) Effects of cannabis regulation in Switzerland: Study protocol of a randomized controlled trial. Frontiers in Psychiatry 14.
Crossref
Crossref
Emmanuel Nii-Boye Quarshie, Nutifafa Eugene Yaw Dey & Kwaku Oppong Asante. (2023) Adolescent suicidal behaviour in Namibia: a cross-sectional study of prevalence and correlates among 3,152 school learners aged 12–17 years. BMC Psychiatry 23:1.
Crossref
Crossref
Nicholas Pintori, Francesca Caria, Maria Antonietta De Luca & Cristina Miliano. (2023) THC and CBD: Villain versus Hero? Insights into Adolescent Exposure. International Journal of Molecular Sciences 24:6, pages 5251.
Crossref
Crossref
Chelsea R. Miller, Bradley G. Burk, Rachel E. Fargason & Badari Birur. (2023) Delta-8-THC association with psychosis: A case report with literature review. Frontiers in Psychiatry 14.
Crossref
Crossref
Andrew F. ScheyerSteven R. LavioletteAnne-Laure PelissierOlivier J.J. Manzoni. (2023) Cannabis in Adolescence: Lasting Cognitive Alterations and Underlying Mechanisms. Cannabis and Cannabinoid Research 8:1, pages 12-23.
Crossref
Crossref
Valerio Ricci, Franca Ceci, Francesco Di Carlo, Ilenia Di Muzio, Laura Ciavoni, Monica Santangelo, Gabriele Di Salvo, Mauro Pettorruso, Giovanni Martinotti & Giuseppe Maina. (2023) First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation. Psychiatry Research 320, pages 115053.
Crossref
Crossref
Esperanza Regueras, Luis Miguel Torres & Ignacio Velazquez. (2023) Cannabinoides y dolor PARTE I. Multidisciplinary Pain Journal, pages 142-162.
Crossref
Crossref
Arundati Nagendra, Abigail C. Wright, Julia Browne, Peter H. Marcus & Corinne Cather. 2023. The Massachusetts General Hospital Handbook of Cognitive Behavioral Therapy. The Massachusetts General Hospital Handbook of Cognitive Behavioral Therapy
273
289
.
Craig Morgan, Alex Cohen, Georgina Miguel Esponda, Tessa Roberts, Sujit John, Joni Lee Pow, Casswina Donald, Bola Olley, Olatunde Ayinde, Joseph Lam, Paramasivam Poornachandrika, Paola Dazzan, Fiona Gaughran, Palaniyandi Ponnusamy Kannan, Selvaraju Sudhakar, Jonathan Burns, Bonginkosi Chiliza, Ezra Susser, Helen A. Weiss, Robin M. Murray, Thara Rangaswamy, Oye Gureje, Gerard Hutchinson, Adejoke Agboola, Olawoye Fadahunsi, Olufemi Idowu, Clement Obuene, Akin Ojagbemi, Bamise Olayiwola, Seyi Owoeye, Kulandaiyesu Amaldoss, Jothi Ramadoss Aynkaran, Abirami Balashanmugam, Premalatha Chockalingam, Kruthika Devanathan, Subhashini Gopal, Ramesh Kumar, Padmavati Ramachandran, Karthick Samikannu, Darielle Bharath-Khan, Donella Jadoo, Elysse Marcellin, Elena Raymond, Grace Sooknanan, Lauren Subnaik & Diana Williams. (2023) Epidemiology of Untreated Psychoses in 3 Diverse Settings in the Global South. JAMA Psychiatry 80:1, pages 40.
Crossref
Crossref
Cara A. Struble, Jacob T. Borodovsky, Mohammad I. Habib, Deborah S. Hasin, Dvora Shmulewitz, Ofir Livne, Claire Walsh, Efrat Aharonovich & Alan J. Budney. (2022) Cannabis practices among a gender-diverse sample of young adults. Drug and Alcohol Dependence Reports 5, pages 100113.
Crossref
Crossref
Ana Fresán, Diana María Dionisio-García, Thelma Beatriz González-Castro, Miguel Ángel Ramos-Méndez, Rosa Giannina Castillo-Avila, Carlos Alfonso Tovilla-Zárate, Isela Esther Juárez-Rojop, María Lilia López-Narváez, Alma Delia Genis-Mendoza & Humberto Nicolini. (2022) Cannabis smoking increases the risk of suicide ideation and suicide attempt in young individuals of 11–21 years: A systematic review and meta-analysis. Journal of Psychiatric Research 153, pages 90-98.
Crossref
Crossref
Sophie K. Stack, Nial J. Wheate & Elise A. Schubert. (2022) Medicinal Cannabis for the Treatment of Anxiety Disorders: a Narrative Review. Current Treatment Options in Psychiatry 9:3, pages 163-173.
Crossref
Crossref
Merle Schüler, Steffen Moritz & Thomas Schnell. (2022) Development and initial validation of a reliable German self‐report measure to assess acute cannabis intoxication‐effects (CanTox‐17). International Journal of Methods in Psychiatric Research 31:3.
Crossref
Crossref
Agnieszka Boroń, Małgorzata Śmiarowska, Anna Grzywacz, Krzysztof Chmielowiec, Jolanta Chmielowiec, Jolanta Masiak, Tomasz Pawłowski, Dariusz Larysz & Andrzej Ciechanowicz. (2022) Association of Polymorphism within the Putative miRNA Target Site in the 3′UTR Region of the DRD2 Gene with Neuroticism in Patients with Substance Use Disorder. International Journal of Environmental Research and Public Health 19:16, pages 9955.
Crossref
Crossref
Alexander Denissoff, Antti Mustonen, Jouko Miettunen, Anni-Emilia Alakokkare, Juha Veijola, James G. Scott, Musa B. Sami & Solja Niemelä. (2022) Trajectories of adolescent psychotic-like experiences and early cannabis exposure: Results from a Finnish Birth Cohort Study. Schizophrenia Research 246, pages 95-102.
Crossref
Crossref
Sorcha Bolton, Dan W. Joyce, Katherine Gordon-Smith, Lisa Jones, Ian Jones, John Geddes & Kate E. A. Saunders. (2022) Psychosocial markers of age at onset in bipolar disorder: a machine learning approach. BJPsych Open 8:4.
Crossref
Crossref
Luis Alameda, Giulia Trotta, Harriet Quigley, Victoria Rodriguez, Romayne Gadelrab, Daniella Dwir, Emma Dempster, Chloe C. Y. Wong & Marta Di Forti. (2022) Can epigenetics shine a light on the biological pathways underlying major mental disorders?. Psychological Medicine 52:9, pages 1645-1665.
Crossref
Crossref
Erin Leach, Larissa B. Fomum Mugri, Man Yee Keung, Lindsey Ouellette, Tiffany Fleeger, Thomas Sapp, Justin Houseman, Megan Hamilton & Jeffrey S. Jones. (2022) Neuropsychiatric effects of cannabis toxicity in the emergency department: A community-based study. The American Journal of Emergency Medicine 56, pages 375-377.
Crossref
Crossref
Linda T. Betz, Nora Penzel & Joseph Kambeitz. (2022) A network approach to relationships between cannabis use characteristics and psychopathology in the general population. Scientific Reports 12:1.
Crossref
Crossref
Lauren Kuhns, Emese Kroon, Karis Colyer-Patel & Janna Cousijn. (2021) Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence. Psychopharmacology 239:5, pages 1231-1249.
Crossref
Crossref
Ruth S. Shim. (2022) Psychotic Disorders and Structural Racism: On Considering Complexity. American Journal of Public Health 112:4, pages 538-540.
Crossref
Crossref
Tessa Robinson, Muhammad Usman Ali, Bethany Easterbrook, Wayne Hall, Didier Jutras-Aswad & Benedikt Fischer. (2022) Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. Psychological Medicine, pages 1-11.
Crossref
Crossref
Joseph Donnelly, Michael Young, Brenda Marshall, Michael L. Hecht & Elena Saldutti. (2022) Public Health Implications of Cannabis Legalization: An Exploration of Adolescent Use and Evidence-Based Interventions. International Journal of Environmental Research and Public Health 19:6, pages 3336.
Crossref
Crossref
Richard L. Price, Kaarina V. Charlot, Sven Frieler, Joseph R. Dettori, Rod Oskouian & Jens R. Chapman. (2022) The Efficacy of Cannabis in Reducing Back Pain: A Systematic Review. Global Spine Journal 12:2, pages 343-352.
Crossref
Crossref
Petter Grahl Johnstad. (2022) Comparative harms assessments for cannabis, alcohol, and tobacco: Risk for psychosis, cognitive impairment, and traffic accident. Drug Science, Policy and Law 8, pages 205032452210952.
Crossref
Crossref
Ofir LivneDvora ShmulewitzAaron L. SarvetMelanie M. WallDeborah S. Hasin. (2022) Association of Cannabis Use–Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001–2002 and 2012–2013. American Journal of Psychiatry 179:1, pages 36-45.
Crossref
Crossref
Hakan Kayir, Jessica Ruffolo, Patrick McCunn & Jibran Y. Khokhar. 2023. Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework. Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework
437
461
.
V. Ricci, F. Ceci, F. Di Carlo, A. Lalli, L. Ciavoni, A. Mosca, G. Sepede, A. Salone, D. Quattrone, S. Fraticelli, G. Maina & G. Martinotti. (2021) Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. Drug and Alcohol Dependence 229, pages 109118.
Crossref
Crossref
Valerio Ricci, Giovanni Martinotti, Franca Ceci, Stefania Chiappini, Francesco Di Carlo, Julius Burkauskas, Ottavia Susini, Debora Luciani, Diego Quattrone, Domenico De Berardis, Mauro Pettorruso, Giuseppe Maina & Massimo Di Giannantonio. (2021) Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms. International Journal of Environmental Research and Public Health 18:23, pages 12632.
Crossref
Crossref
Nicholas Pintori, Maria Paola Castelli, Cristina Miliano, Nicola Simola, Paola Fadda, Liana Fattore, Maria Scherma, Maria Grazia Ennas, Rafaela Mostallino, Giovanna Flore, Marta De Felice, Claudia Sagheddu, Marco Pistis, Gaetano Di Chiara & Maria Antonietta De Luca. (2021) Repeated exposure to JWH‐018 induces adaptive changes in the mesolimbic and mesocortical dopaminergic pathways, glial cells alterations, and behavioural correlates. British Journal of Pharmacology 178:17, pages 3476-3497.
Crossref
Crossref
Grace L. Polkosnik, Maryam Sorkhou & Tony P. George. (2021) Effects of Cannabis Use on Psychotic and Mood Symptoms: A Systematic Review. Canadian Journal of Addiction 12:3, pages 10-21.
Crossref
Crossref
Antti Mustonen, Emily Hielscher, Jouko Miettunen, Alexander Denissoff, Anni-Emilia Alakokkare, James G. Scott & Solja Niemelä. (2021) Adolescent cannabis use, depression and anxiety disorders in the Northern Finland Birth Cohort 1986. BJPsych Open 7:4.
Crossref
Crossref
Markku Lähteenvuo, Albert Batalla, Jurjen J. Luykx, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen & Heidi Taipale. (2021) Morbidity and mortality in schizophrenia with comorbid substance use disorders. Acta Psychiatrica Scandinavica 144:1, pages 42-49.
Crossref
Crossref
Rosa Maria Vitale, Fabio Arturo Iannotti & Pietro Amodeo. (2021) The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets. International Journal of Molecular Sciences 22:9, pages 4876.
Crossref
Crossref
Cynthia A. Fontanella, Danielle L. Steelesmith, Guy Brock, Jeffrey A. Bridge, John V. Campo & Mary A. Fristad. (2021) Association of Cannabis Use With Self-harm and Mortality Risk Among Youths With Mood Disorders. JAMA Pediatrics 175:4, pages 377.
Crossref
Crossref
Fabiana Corsi-Zuelli, Leonardo Marques, Daiane Leite da Roza, Camila Marcelino Loureiro, Rosana Shuhama, Marta Di Forti, Paulo Rossi Menezes, Paulo Louzada-Junior & Cristina Marta Del-Ben. (2021) The independent and combined effects of cannabis use and systemic inflammation during the early stages of psychosis: exploring the two-hit hypothesis. Psychological Medicine, pages 1-11.
Crossref
Crossref
Nevriye A. YesilNevriye A. Yesil. 2021. Drogen haben kurze Beine. Drogen haben kurze Beine
71
103
.
Deborah Hasin & Claire Walsh. (2020) Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review. Journal of Clinical Medicine 10:1, pages 15.
Crossref
Crossref
Rynaz Rabiee, Andreas Lundin, Emilie Agardh, Gunnel Hensing, Peter Allebeck & Anna-Karin Danielsson. (2020) Cannabis use and the risk of anxiety and depression in women: A comparison of three Swedish cohorts. Drug and Alcohol Dependence 216, pages 108332.
Crossref
Crossref
Alain Dervaux. (2020) Cannabis et troubles psychotiques. La Presse Médicale Formation 1:4, pages 394-404.
Crossref
Crossref
Alain Dervaux, Camille De Carvalho & Olivier Cottencin. (2020) Troubles anxieux, troubles dépressifs, conduites suicidaires et cannabis. La Presse Médicale Formation 1:4, pages 384-393.
Crossref
Crossref
Lorra Garey, Hannah Olofsson, Tatyana Garza, Andrew H. Rogers, Brooke Y. Kauffman & Michael J. Zvolensky. (2020) Directional Effects of Anxiety and Depressive Disorders with Substance Use: a Review of Recent Prospective Research. Current Addiction Reports 7:3, pages 344-355.
Crossref
Crossref
David R Alchin. (2020) ‘Vaping psychosis’: Ultra-acute onset of severe, persisting and unusual psychotic symptoms following first-time cannabis vaping in a previously well individual. Australian & New Zealand Journal of Psychiatry 54:8, pages 848-848.
Crossref
Crossref
Robin M. Murray & Wayne Hall. (2020) Will Legalization and Commercialization of Cannabis Use Increase the Incidence and Prevalence of Psychosis?. JAMA Psychiatry 77:8, pages 777.
Crossref
Crossref
J. Helen Cross & Hannah Cock. (2020) A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?. Neuropharmacology 170, pages 107861.
Crossref
Crossref
Farzad Jalilian, Mehdi Mirzaei-Alavijeh, Mohammad Ahmadpanah, Shayan Mostafaei, Mehdi Kargar, Razieh Pirouzeh, Dena Sadeghi Bahmani & Serge Brand. (2020) Extension of the Theory of Planned Behavior (TPB) to Predict Patterns of Marijuana Use among Young Iranian Adults. International Journal of Environmental Research and Public Health 17:6, pages 1981.
Crossref
Crossref
David C. Rettew, Doris C. Gundersen, Erica Kirsten Rapp, Paula Riggs, Christine L. Miller, Monica C. Jackson, Kevin Sabet, Ben Cort & LaTisha L. Bader. 2020. Cannabis in Medicine. Cannabis in Medicine
65
132
.